source
- Amgen's Imdelltra plus AstraZeneca's Imfinzi cuts death risk by 58% in small cell lung cancer Phase 3 trialAmgen reported results from a Phase 3 trial evaluating its investigational therapy Imdelltra in combination with AstraZeneca’s immunotherapy Imfinzi in patients with small cell lung cancer. The st…
- Merck and Moderna present Phase 3 cancer vaccine data at ESMO26 amid Treasury proposal on China investmentEndpoints Weekly reporter Nicole DeFeudis writes from Madrid during the ESMO26 meeting. The most anticipated presentation was a Phase 3 study of a cancer vaccine jointly developed by Merck and Mod…